Ignite Creation Date:
2025-12-24 @ 4:25 PM
Ignite Modification Date:
2025-12-24 @ 4:25 PM
Study NCT ID:
NCT06720766
Status:
RECRUITING
Last Update Posted:
2024-12-06
First Post:
2024-11-27
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity
Sponsor:
The Third People's Hospital of Chengdu
Organization:
Study Overview
Official Title:
Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity
Status:
RECRUITING
Status Verified Date:
2024-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MASLD
Brief Summary:
The non-invasive evaluation of liver steatosis and fibrosis with FibroScan is a routinely procedure in clinical practice for people with obesity. However, there are still considerable uncertainties regarding the potential influence of confounding factors and the optimal application of cut-off values for obesity.
The goal of this observational study is to learn about the optimal application of cut-off values of for Chinese people with obesity.
The goal of this observational study is to learn about the optimal application of cut-off values of for Chinese people with obesity.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| CSY-YNXM-2023-001 | OTHER_GRANT | The Third People's Hospital of Chengdu | View |